A.I. VALI uses proprietary Machine Learning (ML) and Deep Learning (DL) techniques to analyze the data collected from medical images, such as endoscopy video images and tissue biopsies. Our modular A.I. tools empower our clients with accurate, reproducible and affordable platforms at a global level. These platforms have a critical impact in the early detection of cancer in order to provide the best personalized treatment model for each patient. A.I. VALI offers services in research and development, analytical validation, optimization, and validation for regulatory submissions. These services can be utilized by our clients and incorporated into the early stages of drug development through clinical trials and validation of biomarkers, or companion diagnostics (CDx), by providing precise interpretation of information on cell functioning, as well as the structure of critical proteins and biomarkers. Our extensible data science environment and toolkit was built to serve as an architectural framework and community platform for developing and distributing reusable data visualization modules and reusable multi-modality data integration pipelines. Our innovative system allows our team to develop the algorithms, validate them properly, and either commercialize them directly, or support our clients in their efforts to commercialize these products. We are eager to collaborate with researchers and clinical scientists in all medical imaging fields. If you are interested in learning more about how A.I. VALI can help develop or provide a solution for your project, please get in touch with us!
Able Innovations is developing fully automated patient transfer technology to reduce labour and injury costs and improve efficiency, dignity, and quality of life for clients and caregivers alike. Our autonomous and intelligent transfer devices will be able to lift and transfer humans in a safe, efficient, and dignified manner, with zero physical effort required from caregivers. By performing safe and effortless automated transfers, our technology will help to reduce the $30 billion annual financial burden to healthcare facilities that result from the high injury rates and labour expenditure resulting from the inefficient, unsafe, and outdated patient transfer devices in use today. Our first product, the DELTA Platform, will leverage our unique transfer method to perform automated lateral transfers in hospitals and other healthcare facilities, allowing these facilities to save millions on injury costs and optimize their labour resources to achieve the greatest clinical and social outcomes for their clients. Using this same core transfer technology, we plan to develop intelligent and robust mobility devices for long-term care and homecare use, which will enable individuals with impaired mobility to live their lives with a hereto unprecedented level of dignity and independence.
AceAge is a healthcare technology company, creating intuitive products to ease the aging process and improve health outcomes. AceAge is the company behind the next innovation in healthcare technology. Its upcoming product is a home health appliance designed to help people take their medication properly. Karie is a personal health companion that organizes, schedules, and dispenses pills with easy one-button control. The CEO of AceAge, Spencer Waugh, created Karie to increase the health and safety of medical patients, and as a way to minimize the negative consequences of missed medications or general failure to adhere to medication directions. The success of medicine is dependent on the patient’s compliance with the medical directions that accompany it, making it an integral part of healthcare. The total direct and indirect costs of nonadherence in the US annually is $290 billion. By making daily medicine routines completely automated, Karie removes the chance of human error. Karie uses common multi-dose pouch packaging that can be pre-set by pharmacists. Doses are scheduled, delivered and monitored for the user. Karie is easy to use, enables greater patient autonomy and ensures better healthcare through a highly coordinated program.
The best anti-aging resource is your own younger cells. Personalized regenerative medicine is the opportunity to leverage strategies that tap into the power of our own cells to treat our bodies. Our cells have the potential to rejuvenate skin, replenish hair, and even help fight disease. Preserving your own cells today can give you access to your own younger cells to use in revolutionary treatments for the rest of your life.
AmacaThera is a clinical-stage company based in Toronto. AmacaThera is redefining how therapeutics are delivered. AmacaThera has developed a platform hydrogel technology that addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. AmacaThera’s lead product addresses post-operative pain and consequently may have an impact on the opioid crisis.